Rainbow BioSciences, LLC Prepares Term Sheet to Present to Amarantus BioSciences, Inc.

NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), announced today that it has prepared a joint venture term sheet for presentation to Amarantus BioSciences (OTCBB: AMBS), the makers of a revolutionary new diagnostic platform for Parkinson’s disease. If the term sheet is approved by Amarantus, both parties will move forward with a joint venture agreement as soon as possible, said RBCC CEO Patrick Brown. The first project planned for the joint venture will be the commercialization of NuroPro, a sophisticated new test developed to more accurately and easily diagnose Parkinson’s disease. NuroPro works by identifying differentiated levels proteins and peptides in the blood of patients who have the disease.